J Stephen Dickson MRPharmS

All discussion in this presentation is from a personal viewpoint and should not be taken as general medical advice without referring to a registered medical professional.

UK: +44 141 404 6545

www.dicksonchemist.co.uk

superintendent@dicksonchemist.co.uk

First patent for opiate blocking drug was for Naloxone in 1966.


WHO list of essential medicines – still there 50 years later

Its orally more active analog Naltrexone shown on the right.

B>C>A

C>B>A

A>C>B




G-Protein Family
Opiates
Somatostatin
TLR
Glucagon
Beta-Adrenergic

Etc (generally inhibitory when activated)


Multitude of outcomes


Opiate receptors in specific



AGONIST Fits and Activates (Variable)

Partial agonist -fits but doesnt fully activate





Use of Naltrexone as therapy for addiction

50-300mg daily Licensed


Very successful – blocked all euphoric effects of heroin etc.

Short acting, so compliance often poor

Blocked natural endorphins, lead to dysphoria in some patients.

Recent resurgence in opiate antagonists for alcoholism Licensed

Naltrexone Immunological effects




Drugs are rarely 100% selective

Often after launch, drugs undergo an elucidation period where previously unknown effects are found.

Science often improves – which assists this process.

Drugs which affect homeostasis can have different results in higher and lower doses

Naltrexone Immunological effects




Drugs are three dimensional. (Chiral)

Usually synthesised in 50:50 raecemic mixture of L and R isomers.

Different ISOMERS can have different pharmacological targets

Naltrexone Immunological effects



Naltrexone Immunological effects 1986 -> now Dr Ian Zagon



Endorphin receptors are present on vast array of immune cells

Endorphin receptors are coded in the mRNA of immune cells, important in regulating the biological response to infection and mutagens.

~30 years of research and ~300 papers the science is irrefutable

Naltrexone Immunological effects Zagon research summary



Many outward diseases
Are expressions of
Malfunctioning immune
system

Blocking opiate receptors briefly using naltrexone causes an up-regulation in the production of endorphins, which can act in an immunomodulatory way to correct immune system malfunction

The immune system is regulated by Endorphins - acting primarily on Opiate receptors

Cell proliferation is mediated by a subtype of endorphins. Important in cancer?

Naltrexone Immunological effects Experimental Models

Wound Healing

MS

Ocular surface disease

Chrohn's Disease

Pancreatic Cancer

Breast Cancer



This list grows constantly and is not exhaustive...

Naltrexone Immunological effects Toll Like Receptors




Demonstrated first in 1985 by Christiane Nüsslein-Volhard.

Present on immune cells all over the body, macrophages, dendritic cells, neutrophils, blymphocytes, mast cells, monocytes, and on various internal organs.


First line defense against invasion from bacteria and other pathogens

Can produce NF-Kappa-B as part of the signaling mechanism.

Naltrexone Immunological effects Toll Like Receptors



Low Dose Naltrexone (0.1-5mg)



Chronic Pain

LEVO Naltrexone

Upregualtion of Endorphins

- → Central CNS release of dopamine
- → Suppression of Inflammatory cytokines

DEX Naltrexone

Suppress cytokine Mediated immune System

Suppress NF-Kappa-B & reduce Inflammation

(Gial cell?)

CRP Syndrome

Fibromyalgia

Nerve damage

ALS

CNS Dompanergic

LEVO Naltrexone

Upregualtion of Endorphins

- → Central CNS release of dopamine
- → Improvement of Mood
- → Enhancement Of GABA

DEX Naltrexone

?

Depression

Anxiety

Parkinsons

Alzeimers?

Cancer

Upregulation of immunoregulatory genes
Downregulation of some oncogenes
Inhibition of growth (direct)
Inhibition of angioenesis
Direct apoptosis
Sensitisation of cells to chemo

Autoimmune

LEVO Naltrexone

Upregualtion of Endorphins

– immunomodulation.

OGF

Atypical Antiinflammatory

DMARD?

DEX Naltrexone

Inhibition of TLR4 (downregulation of Immune responses)

Suppress cytokine Mediated immune System

Suppress
NF-Kappa-B & reduce
Inflammation

MS

Crohns

Hashimotos

+myriad

RECENT RESEARCH 2018

Mitchell R. K. L. Lie et al, Published March 2018 (Human clinical trial)

RESULTS: Low dose Naltrexone induced clinical improvement in 74.5%, and remission in 25.5% of patients. Naltrexone improved wound healing and reduced ER stress induced by Tunicamycin, lipopolysaccharide or bacteria in epithelial barriers. Inflamed mucosa from IBD patients showed high ER stress levels, which was reduced in patients treated with LDN. Cytokine levels in neither epithelial cells nor serum from IBD patients were affected.

Guttorm Raknes et al, Published January 2018 (Retrospective human)

RESULTS: We identified 582 IBD patients. Among the 256 patients that became persistent LDN users, there were reductions in number of users of all examined drugs (-12%), intestinal anti-inflammatory agents (-17%), other immunosuppressants (-29%), intestinal corticosteroids (-32%), and aminosalicylates (-17%). In subgroups with identified CD and UC patients, there were significant reductions in number of users of intestinal corticosteroids (CD: -44%, UC: -53%) and systemic corticosteroids (UC: -24%).

Severine Cao; Evelyn Lilly; Steven T. Chen (Harvard Medical) Jan 2018

RESULTS: The recent report of 2 case series demonstrating the efficacy of low-dose naltrexone in the treatment of HHD represents exciting progress in the management of a disease with limited therapeutic options. Herein we present 3 additional cases of HHD demonstrating varying responses to naltrexone

RECENT RESEARCH 2017-2018


Ludwig MD, Zagon IS, McLaughlin PJ Jan 2018 (Animal)


RESULTS: Modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) alters inflammatory cytokine expression in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Multiplex cytokine assays demonstrated that mice with chronic EAE and treated with either OGF or low-dose naltrexone (LDN) had decreased expression of interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and the anti-inflammatory cytokine IL-10 within 10 days or treatment, as well as increased serum expression of the pro-inflammatory cytokine IL-6, relative to immunized mice receiving saline. Multiplex data were validated using ELISA kits and serum from MS patients treated with LDN and revealed decreased in IL-6 levels in patients taking LDN relative to standard care alone. These data, along with serum levels of OGF, begin to formulate a selective biomarker profile for MS that is easily measured and effective at monitoring disease progression and response to therapy.

Luke Parkitny and Jarred Younger – April 2017

RESULTS: We found that LDN was associated with reduced plasma concentrations of interleukin (IL)-1, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p40, IL-12p70, IL-15, IL-7A, IL-27, interferon (IFN)-, transforming growth factor (TGF)-, TGF-, tumor necrosis factor (TNF)-, and granulocyte-colony stimulating factor (G-CSF). We also found a 15% reduction of FM-associated pain and an 18% reduction in overall symptoms. The findings of this pilot trial suggest that LDN treatment in fibromyalgia is associated with a reduction of several key pro-inflammatory cytokines and symptoms.


Total daily doses of LDN (UK)






Number of Unique GMC Numbers

UK data 2014 - 2018




Top 22 Disease Consultation Requests


(5 months - 1200 patients)



Disease groups (5 months data)



Clinical Practice Guidelines





Chronic Pain

Nerve pain

CRPS

Spinal pain

Neuralgia

Post viral ME/CFS Fibro

Withdraw opiates gently. Replace with nefopam if required.

Review use of gabapentin, pregabalin, SSRI, tricyclics, Tylenol. Consider MDS to get a baseline.

Explain use of pain diary or similar tool. Make it compulsory for repeats.

Start at 1mg, increase weekly to 3mg then review. Increase to 4.5mg after successful result.

Discontinue after 3/12 if no improvement



CNS

Only consider when patient has been stable for 3/12

Manage expectations. i.e. parkinsons and depression

Depression

Parkinsons

?Alzeimers

?ALS

Use local tool to assess mood and energy levels

Start at 1mg, increase weekly to 3mg then review. Increase to 4.5mg after successful result.

Review monthly for 1st 6 months



Cancer

Adenoma

Breast

Lung

Glio

Lymphoma

Ovarian

Melanoma

Recent LFT and renals if acute

Communicate with oncologists directly where possible. Avoid working in isolation.

Review evidence for their specific disease – is there a trial with more in vivo evidence? Biologics? Notes!.

Start at 1mg, rapid titration – mane dosing – advise Of side effects including headache.

Look at the recent trials for LDN



Cancer

Adenoma

Breast

Lung

Glio

Lymphoma

Ovarian

Melanoma

Daily LDN and 3 days / off with CBD or canabinoids

Concomitant with most chemo improves outcome In vitro. Remember Vit D! Beta Glucan! ALA?

Consider repo and synergistic drugs: mTOR inhibitors, Resveratrol, Simvastatin, Doxycycline, Metformin, Mebendazole, Dipyridamole?

Have you double checked that the patient completed, failed or formally refused standard treatment?

Not a time for being conservative!



Autoimmune

Withdraw opiates. Replace if required. Discuss potential outcomes.

Use the forums to direct patients to decide for themselves. Doctors should not be "salespeople" in this scenario.

Normally start at 1mg,increasing weekly by 1mg. Except CFS and HASHIMOTOS

Hashimotos – start at 0.5mg. Increase gradually at 0.5 Weekly. Refer to endocrinologist or test for levels.

RISK OF HYPER IS HIGH

Mitigate your risk!

MS CFS ME HASHIMOTOS RA ALS +rest



Autoimmune

CFS – flu symptoms common. Slow initiation – morning Dosing. Reduce down when flu symptoms occur!

MS – counsel of worsening symptoms for 1st 3 months.

Don't be afraid to have a rest!

Night-time dosage appears unimportant in clinical response.

MS CFS ME HASHIMOTOS RA ALS +rest

Omega-3, Vit D! - check the biomarkers yourself if possible, CRP etc Repeat in 1, 3 6 and 12 months!

Add one thing at a time!

Make sure you know what is working.



Autoimmune

Why try it for any autoimmune disease?
TLR Blockade dampens down the 1st entry to immune
System by invaders. Rationale enough?

Speak to colleagues. Don't apologise. Evangelise when patients do well!

Befriend the support nurses, charities and groups Supporting your patient.

Start with Liquid, tabs or caps, if side FX try Sublingual.
No scientific reason creams would work or have
Systemic bioavailability.

Beware of prescribing for children

MS CFS ME HASHIMOTOS RA ALS +rest



Fight the nonsense!

Is it slow release?

I can't have slow Release!

I'm chemosensitive!

You have to take
It at night and
Suffer the
nightmares

I get side effects From everything!

See licensed Drug at 300mg

My friend said...

Is it gluten free?

Are the capsules Vegan?



Every patient is special!

Forget what you read on the Internet

This is a real drug, its not homeopathy

Time of day likely irrelevant

Your recording of symptoms is Important! LDN APP!

No miracles here



Case Reports

```
Endorphin levels suppressed in autoimmune model – restored by LDN
                ttps://www.ncbi.nlm.nih.gov/28766982
      Reduced Inflammatory markers after treatment with LDN
               :p://www.mdpi.com/2227-9059/5/2/16/pdf)
           Pain reduction demonstrated in fibro with LDN
      Evidence of improvements in major depressive episodes
  Glioblastoma – significant unexpected survival beyond bell curve
                      Neuropathic pain in TM
```

Recent personal experience

30s Male. MS – wheelchair, limited movement. 4 weeks, brain fog lifted, 8 weeks, improved Bladder control, 12 weeks now able to walk unassisted for short distances. LDN

Breast cancer 60s female – follow up after 5 years post terminal diagnosis. LDN + metformin

Malignant melanoma – 70s Female – Alive and well 7 years post diagnosis and surgery LDN

Gastric cancer – 60s male – stable disease 3-6 months after terminal diagnosis Cannabinoids Beta glucan, LDN.

Hashimotos – myriad of patients – huge improvements, reduced Levo and Lio. Well.

CFS/ME/Fibro – 100s – well, often back at work. Stop LDN, get sick again. Repeatable.

Arthritis – 60s Male – remarkable reduction in CRP after 8 weeks LDN. Stopped pain relief. Stopped LDN, CRP rose. Repeatable.